OBJECTIVES: To determine the characteristics of adult-onset autoimmune chorea, and compare paraneoplastic and idiopathic subgroups. METHODS: Thirty-six adults with autoimmune chorea were identified at Mayo Clinic (Rochester, MN) from 1997 to 2012. Medical record and laboratory data were recorded. Nonparaneoplastic (n = 22) and paraneoplastic cases (n = 14) were compared. RESULTS: Women accounted for 21 patients (58%). Median age at symptom onset was 67 years (range 18-87 years). We estimated the incidence for Olmsted County was 1.5 per million person-years. Symptom onset was subacute in all. Chorea was focal (20 patients) or generalized (16 patients). Although chorea predominated, other neurologic disorders frequently coexisted (29 patients); abnormal eye movements were uncommon (4 patients). No patient had NMDA receptor antibody or any immunoglobulin (Ig)G yielding a detectable immunofluorescence binding pattern restricted to basal ganglia. Two had synaptic IgG antibodies novel to the context of chorea (GAD65, 1; CASPR2, 1). In the paraneoplastic group, 14 patients had evidence of cancer. Of 13 with a histopathologically confirmed neoplasm, small-cell carcinoma and adenocarcinoma were most common; 6 patients had a cancer-predictive paraneoplastic autoantibody, with CRMP-5-IgG and ANNA-1 being most common. In the idiopathic group, 19 of the 22 patients had a coexisting autoimmune disorder (most frequently systemic lupus erythematosus and antiphospholipid syndrome); autoantibodies were detected in 21 patients, most frequently lupus and phospholipid specificities (19 patients). The paraneoplastic group was older (p = 0.001), more frequently male (p = 0.006), had more frequent weight loss (p = 0.02), and frequently had peripheral neuropathy (p = 0.008). CONCLUSIONS: Autoimmune chorea is a rare disorder with rapid onset. Male sex, older age, severe chorea, coexisting peripheral neuropathy, and weight loss increase the likelihood of cancer.
OBJECTIVES: To determine the characteristics of adult-onset autoimmune chorea, and compare paraneoplastic and idiopathic subgroups. METHODS: Thirty-six adults with autoimmune chorea were identified at Mayo Clinic (Rochester, MN) from 1997 to 2012. Medical record and laboratory data were recorded. Nonparaneoplastic (n = 22) and paraneoplastic cases (n = 14) were compared. RESULTS:Women accounted for 21 patients (58%). Median age at symptom onset was 67 years (range 18-87 years). We estimated the incidence for Olmsted County was 1.5 per million person-years. Symptom onset was subacute in all. Chorea was focal (20 patients) or generalized (16 patients). Although chorea predominated, other neurologic disorders frequently coexisted (29 patients); abnormal eye movements were uncommon (4 patients). No patient had NMDA receptor antibody or any immunoglobulin (Ig)G yielding a detectable immunofluorescence binding pattern restricted to basal ganglia. Two had synaptic IgG antibodies novel to the context of chorea (GAD65, 1; CASPR2, 1). In the paraneoplastic group, 14 patients had evidence of cancer. Of 13 with a histopathologically confirmed neoplasm, small-cell carcinoma and adenocarcinoma were most common; 6 patients had a cancer-predictive paraneoplastic autoantibody, with CRMP-5-IgG and ANNA-1 being most common. In the idiopathic group, 19 of the 22 patients had a coexisting autoimmune disorder (most frequently systemic lupus erythematosus and antiphospholipid syndrome); autoantibodies were detected in 21 patients, most frequently lupus and phospholipid specificities (19 patients). The paraneoplastic group was older (p = 0.001), more frequently male (p = 0.006), had more frequent weight loss (p = 0.02), and frequently had peripheral neuropathy (p = 0.008). CONCLUSIONS:Autoimmune chorea is a rare disorder with rapid onset. Male sex, older age, severe chorea, coexisting peripheral neuropathy, and weight loss increase the likelihood of cancer.
Authors: R A Asherson; R H Derksen; E N Harris; B N Bouma; A E Gharavi; L Kater; G R Hughes Journal: Semin Arthritis Rheum Date: 1987-05 Impact factor: 5.532
Authors: Sean J Pittock; Claudia F Lucchinetti; Joseph E Parisi; Eduardo E Benarroch; Bahram Mokri; Christina L Stephan; Kwang-Kuk Kim; Manfred W Kilimann; Vanda A Lennon Journal: Ann Neurol Date: 2005-07 Impact factor: 10.422
Authors: V A Lennon; T J Kryzer; G E Griesmann; P E O'Suilleabhain; A J Windebank; A Woppmann; G P Miljanich; E H Lambert Journal: N Engl J Med Date: 1995-06-01 Impact factor: 91.245
Authors: Nicholas L Zalewski; Vanda A Lennon; Daniel H Lachance; Christopher J Klein; Sean J Pittock; Andrew Mckeon Journal: Muscle Nerve Date: 2016-02-08 Impact factor: 3.217
Authors: Manoj K Mittal; Alejandro A Rabinstein; Sara E Hocker; Sean J Pittock; Eelco F M Wijdicks; Andrew McKeon Journal: Neurocrit Care Date: 2016-04 Impact factor: 3.210
Authors: William Oliver Tobin; Vanda A Lennon; Lars Komorowski; Christian Probst; Stacey Lynn Clardy; Allen J Aksamit; Juan Pablo Appendino; Claudia F Lucchinetti; Joseph Y Matsumoto; Sean J Pittock; Paola Sandroni; Maja Tippmann-Peikert; Elaine C Wirrell; Andrew McKeon Journal: Neurology Date: 2014-10-15 Impact factor: 9.910